Physicians' Academy for Cardiovascular Education

GLP-1 agonist lowers CV biomarkers in high-risk T2DM patients

Liraglutide effects on cardiovascular risk biomarkers in patients with type 2 diabetes and albuminuria: A sub-analysis of a randomised, placebo-controlled, double-blind, cross-over trial

Literature - von Scholten BJ, Persson F, Rosenlund S, et al. - Diabetes Obes Metab. 2017; published online ahead of print

Main results

Conclusion

In T2DM patients with albuminuria, liraglutide treatment was associated with reductions in circulating levels of CV risk biomarkers TNF-alpha, MR-proADM and MR-proANP. These findings support the hypothesis that liraglutide treatment may be associated with the reduction of inflammatory and CV risk biomarkers in high-risk patients.

References

Show references

Find this article online at Diabetes Obes Metab

Share this page with your colleagues and friends: